<!doctype html>

<html lang="en">
<head>
    <meta charset="utf-8">
    <meta content="IE=edge" http-equiv="X-UA-Compatible">
    <meta content="width=device-width, initial-scale=1.0" name="viewport">
    <title>GA TB Reference Guide </title>
    <meta content="GA TB Reference Guide" name="description">
    <meta content="SitePoint" name="author">
    <link href="../assets/uikit.css" rel="stylesheet">
    <link href="../assets/style.css" rel="stylesheet">
</head>

<body>
<div class="uk-container">
    <div class="chapter-header">
        <div class="header-title">
            <div>
                <img src="ic_chart.svg"  class="ic_chapter_icon">
            </div>
            <p class="chapter-title">12. Clinical Situations for which Standard Therapy cannot be given or is not well-tolerated or may not be effective: Potential Alternative Regimens (Dosing and/or Drugs)</p>
        </div>
        <p> <span class="view-in-chapter-highlight"> View in chapter → <span> <a href="5_treatment_of_current_(active)_disease_therapy__c__special_clinical_situations.html#table12"> Special Clinical Situations </a></p>
        <p class="last-updated"><i>Last Updated October 2025</i></p>
    </div>
    <hr>
    <div class="uk-overflow-auto" id="table_12_clinical_situations_for_which_standard_therapy_cannot_be_given_or_is_not_well_tolerated">
        <div class="uk-tabs-container">
            <div class="tabs">
                <button class="tab-button" onclick="switchTab(0, event)">Critical illness requiring vasopressors</button>
                <button class="tab-button" onclick="switchTab(1, event)">Proven or suspected meningeal TB</button>
                <button class="tab-button" onclick="switchTab(2, event)">Patient age 75 years or greater¹</button>
                <button class="tab-button" onclick="switchTab(3, event)">Disseminated TB with concern for poor absorption¹</button>
                <button class="tab-button" onclick="switchTab(4, event)">Patient receiving medications via nasogastric or PEG tube¹</button>
                <button class="tab-button" onclick="switchTab(5, event)">Baseline elevation of liver enzymes¹</button>
                <button class="tab-button" onclick="switchTab(6, event)">Acute hepatitis after starting standard therapy¹</button>
            </div>

            <div class="tab-content">
                <table class="uk-table uk-table-small uk-table-divider">
                    <tbody>
                    <tr>
                        <th class="uk-text-nowrap">Concerns Raised</th>
                        <td>Poor gut medication absorption</td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Regimen</th>
                        <td>
                            <ul>
                                <li>IV rifampin ≥ 10 mg/kg daily</li>
                                <li>PO pyrazinamide UD</li>
                                <li>PO ethambutol UD</li>
                            </ul>
                            Consider adding at least two of the following agents.
                            <ul>
                                <li>IV isoniazid UD <span class="info-icon" data-tooltip="NOTE: Limited availability Associated with peripheral neuropathy. Add B6 ≥50 mg/daily" >i</span></li>
                                <li>IV levofloxacin or moxifloxacin UD</li>
                                <li>IV linezolid UD <span class="info-icon" data-tooltip="NOTE: Associated with irreversible peripheral and optic neuritis. Add B6 ≥ 50 mg/daily" >i</span></li>
                                <li>IV amikacin UD <span class="info-icon" data-tooltip="NOTE: Associated with otovestibular toxicity">i</span></li>
                            </ul>
                        </td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Comments</th>
                        <td>
                            <ul>
                                <li>Oral medications are generally poorly bioavailable among critically ill patients.</li>
                                <li>Patients receiving sedation are unable to report isoniazid or linezolid-induced neuropathies nor aminoglycoside- induced otovestibular toxicity</li>
                            </ul>
                        </td>
                    </tr>
                    </tbody>
                </table>
            </div>

            <div class="tab-content">
                <table class="uk-table uk-table-small uk-table-divider">
                    <tbody>
                    <tr>
                        <th class="uk-text-nowrap">Concerns Raised</th>
                        <td>Rapidly progressive and often fatal. High plasma levels needed to achieve adequate CNS penetration.
                            High index of suspicion necessary; microbiological diagnostic tests have low yield.</td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Regimen</th>
                        <td>
                            <ul>
                                <li>IV rifampin ≥ 10 mg/kg daily</li>
                                <li>PO or IV <span class="info-icon" data-tooltip="NOTE: Limited availability">i</span> isoniazid UD</li>
                                <li>PO pyrazinamide UD PO ethambutol UD (adults)</li>
                                <li>PO ethionamide (children)</li>
                            </ul>
                            <p>Consider adding IV levofloxacin or moxifloxacin UD in lieu of ethambutol, especially if there is concern for isoniazid-resistant TB.</p>
                        </td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Comments</th>
                        <td>Rifampin has poor CNS penetration but is an essential drug for meningeal TB treatment. Isoniazid,
                            pyrazinamide, levofloxacin, and moxifloxacin have excellent CNS penetration.
                            <p>Ethambutol has poor CNS penetration. Early use of fluoroquinolones has been associated with
                                improved outcomes among patients with isoniazid-resistant meningeal TB</p></td>
                    </tr>
                    </tbody>
                </table>
            </div>

            <div class="tab-content">
                <table class="uk-table uk-table-small uk-table-divider">
                    <tbody>
                    <tr>
                        <th class="uk-text-nowrap">Concerns Raised</th>
                        <td>Increased risk for pyrazinamide-induced hepatotoxicity</td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Regimen</th>
                        <td>Can consider rifampin, isoniazid, and ethambutol without pyrazinamide when drug-susceptibility is
                            known and/or patient has low burden of disease</td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Comments</th>
                        <td>3-drug regimens may increase risk of failure or acquired drug-resistance.</td>
                    </tr>
                    </tbody>
                </table>
            </div>

            <div class="tab-content">
                <table class="uk-table uk-table-small uk-table-divider">
                    <tbody>
                    <tr>
                        <th class="uk-text-nowrap">Concerns Raised</th>
                        <td>Disseminated TB is associated with gut edema which decreases po medication bioavailability</td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Regimen</th>
                        <td>Standard 4-drug regimen Consider increasing po Rifampin dose (15 to 20 mg/kg daily, minimum 600 mg)
                            Consider IV rifampin and IV isoniazid <span class="info-icon" data-tooltip="NOTE: Some of these recommendations differ or are not addressed by 2016 ATS/CDC/IDSA drug-susceptible TB guidelines. Drug-susceptibility testing for second-line drugs should be requested if these agents are used." data-tooltip-position="tooltip-left">i</span> for inpatients.</td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Comments</th>
                        <td>Consider obtaining TB drug levels in ensure po dosing achieves at least minimum levels</td>
                    </tr>
                    </tbody>
                </table>
            </div>

            <div class="tab-content">
                <table class="uk-table uk-table-small uk-table-divider">
                    <tbody>
                    <tr>
                        <th class="uk-text-nowrap">Concerns Raised</th>
                        <td>Tube feeds may decrease TB drug bioavailability</td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Regimen</th>
                        <td>No change in standard TB regimen</td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Comments</th>
                        <td>Hold tube feeds ≤2 hours prior and ≥1 hour after TB drug intake. Longer intervals are needed if quinolone- containing regimens are given with divalent-cation containing tube feeds</td>
                    </tr>
                    </tbody>
                </table>
            </div>

            <div class="tab-content">
                <table class="uk-table uk-table-small uk-table-divider">
                    <tbody>
                    <tr>
                        <th class="uk-text-nowrap">Concerns Raised</th>
                        <td>Consider limiting number of hepatotoxic drugs for patients with baseline ALT>3x UNL and/or advanced
                            liver disease.
                            Order of hepatotoxicity: PZA>INH>RIF</td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Regimen</th>
                        <td>
                            <ul>
                                <li>RIF/INH/EMB +/- FQN</li>
                                <li>RIF/EMB/FQN +/- LZD or AG</li>
                                <li>EMB/FQN +/- LZD or AG</li>
                            </ul>
                        </td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Comments</th>
                        <td>
                            Consider baseline liver enzyme elevation could be due to hepatic TB <br> <br>
                            3-drug regimens may increase risk of failure or acquired drug-resistance.
                        </td>
                    </tr>
                    </tbody>
                </table>
            </div>

            <div class="tab-content">
                <table class="uk-table uk-table-small uk-table-divider">
                    <tbody>
                    <tr>
                        <th class="uk-text-nowrap">Concerns Raised</th>
                        <td>TB drug-induced hepatotoxicity
                            Stop TB drugs if ALT>3x UNL and patient symptomatic or ALT >5x UNL regardless of symptoms</td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Regimen</th>
                        <td>Sequential re-introduction of TB drugs once ALT <2x UNL. <br>
                            (1) Rifamycin x 5-7 days <br>
                            (2) Isoniazid x 5-7 days <br>
                            (3) Ethambutol x 5-7 days <br>
                            (4) Need and choice of 4th agent depends on burden of disease and drug-susceptibility pattern.
                        </td>
                    </tr>
                    <tr>
                        <th class="uk-text-nowrap">Comments</th>
                        <td>Pyrazinamide is often the culprit and effective regimens can be designed without this drug.
                            Rifamycins are the drugs most important for sterilizing activity (i.e., cure) in TB treatment.
                            Consider adding a 4th drug if patient has high burden of disease.</td>
                    </tr>
                    </tbody>
                </table>
            </div>

            <p>Abbreviations: UD, usual dose; UNL, upper normal limit.</p>

            <p>Additional Notes: <br>
                These recommendations are meant for patients with known drug-susceptible TB or at low risk for drug- resistant TB</p>
        </div>
    </div>
</div>
</body>
<script src="../assets/uikit.js" type="text/javascript"></script>
<script src="../assets/uikit-icons.js" type="text/javascript"></script>
<script src="main.js" type="text/javascript"></script>
<script>
// Initialize the first tab as active
document.addEventListener('DOMContentLoaded', function() {
    const tableContainer = document.getElementById('table_12_clinical_situations_for_which_standard_therapy_cannot_be_given_or_is_not_well_tolerated');
    activateTab(tableContainer, 0);
});
</script>
</html>
